Cerebrovascular accident in β-thalassemia major (β-TM) and β-thalassemia intermedia (β-TI)

American Journal of Hematology

Volumn 83, Issue 1, 2008, Pages 77-79

  Karimi, Mehran ^a   Khanlari, Maryam ^a   Rachmilewitz, Eliezer A ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b WOLFSON MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DEFEROXAMINE; FERRITIN; HEPARIN; INSULIN; NIMODIPINE; WARFARIN;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; BLEEDING; BLOOD TRANSFUSION; BRAIN DAMAGE; BRAIN INFARCTION; BRAIN VASOSPASM; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHILD; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEMOCHROMATOSIS; HUMAN; ISCHEMIA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PRIORITY JOURNAL; RISK FACTOR; SPLENECTOMY; SUBARACHNOID HEMORRHAGE; THROMBOEMBOLISM; TREATMENT DURATION;

ADOLESCENT; ADULT; BETA-THALASSEMIA; BRAIN; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 38349045177     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20938     Document Type: Article

References (13)

1. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187-1193.
2. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood 2002;99:36-43.
3. Manfre L, Giarratano E, Maggio A, et al. MR imaging of the brain: Findings in asymptomatic patients with thalassemia intermedia and sickle cell-thalassemia disease. Am J Roentgenol 1999;173:1477-1480.
4. Karimi M, Yarmohammadi H, Farjadian S, et al. β-thalassemia intermedia from southern Iran: IVS-II-I (G→A) is the prevalent thalassemia intermedia allele. Hemoglobin 2002;2:147-154.
5. Cappellini MD, Robbiolo L, Bottasso BM, et al. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassemia intermedia. Br. J Haematol 2000:111:467-473.
6. Tahar A, Mehio G, Bignamini D, et al. The incidence of thromboembolic events among 8860 patients with thalassemia major and intermedia in the Mediterranean area and Iran. Blood 2004;104(Suppl 1):3623 (abstract).
7. Borenstain-Ben Yashar V, Barenholz Y, Hy-Am E, et al. Phosphatidylserine in the outer leaflet of red blood cells from β-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes. Am J Hematol 1993;44:63-65.
8. Eldor A, Lellouche F, Goldfarb A, et al. In vivo platelet activation in β-thalassemia major reflected by increased platelet-thromboxane urinary metabolites. Blood 1991;77:1749-1753.
9. Stroke prevention in atrial fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high risk patients with atrial fibrillation. Stroke prevention in atrial fibrillation III randomized clinical trial. Lancet 1996;348:633-638.
10. Deugnier Y. Human hepatic iron overload syndromes. Bull Acad Natl Med 2005;189:1665-1676.
11. Berner A, Kamran S. Association between stroke and acute myocardial infarction and its related risk factors: Hypertension and diabetes mellitus. Anadolu Kardiol Derg 2006;6:24-27.
12. Wasi P, Pootrakul P, Pianki Jagum A, et al. A syndrome of hypertension, convulsions and cerebral hemorrhage in thalassemic patients after multiple blood transfusions. Lancet 1978;2:602.
13. Gurgey A, Kalayci O, Gumruk F, et al. Convulsion after blood transfusion in four β thalassemia intermedia patients. Pediatr Hematol Oncol 1994;11:549-552.